Let's focus on what we can do!

By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis – Labiotech.eu

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis – Labiotech.eu

Sunday, 17 March, 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis – Labiotech.eu

[responsivevoice_button voice="UK English Female" buttontext="Listen to Post”]

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research.

GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, a condition that damages the nervous system and causes progressive disability.

Last year, GeNeuro reported that the drug reduced the rate of brain tissue loss after one year in a phase IIb clinical trial in patients with multiple sclerosis. The company then extended the trial, continuing to treat 220 of the patients for up to another two years to test the drug’s long term effects.

Results from the extension trial were encouraging for GeNeuro. The drug’s benefits continued over the two year extension, and there were even signs of the drug slowing the progression of the disability for the first time.

This long-term effect may indicate that GeNeuro’s approach produces gradual but long-lasting results. The initial trial of the drug failed to show any benefits after six months, which prompted GeNeuro’s collaboration partner company Servier, which funded the trial, to pull out from the partnership for “strategic reasons.” However, benefits were seen after one year of treatment.

Read more at: https://labiotech.eu/medical/multiple-sclerosis-geneuro-viral/

Categories :
  • Latest Headlines
  • Multiple Sclerosis
Socials :

Recent posts